Alpha 1-antitrypsin deficiency natural history, complications, and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
If left untreated, not all patients with [[Gene|deficient gene]] develop [[Emphysema|symptomatic emphysema]] or [[cirrhosis]]. In [[symptomatic]] [[patients]], the median time between [[observation]] of [[symptoms]] and [[diagnosis]] is approximately 8 years.The [[symptoms]] of alpha1-antitrypsin deficiency (AATD) in the first two decades of life are mainly of associated [[Liver diseases|liver disease]] progressing to [[Pulmonary|pulmonary manifestations]] appear later in life. [[Emphysema]] | If left untreated, not all patients with [[Gene|deficient gene]] develop [[Emphysema|symptomatic emphysema]] or [[cirrhosis]]. In [[symptomatic]] [[patients]], the median time between [[observation]] of [[symptoms]] and [[diagnosis]] is approximately 8 years. The [[symptoms]] of alpha1-antitrypsin deficiency (AATD) in the first two decades of life are mainly of associated [[Liver diseases|liver disease]] progressing to [[Pulmonary|pulmonary manifestations]] appear later in life. [[Emphysema]] is seen in non-smokers in the fifth decade of life and during the fourth decade of life in smokers. Less common associations are [[panniculitis]] and [[Anti-neutrophil cytoplasmic antibody|cytoplasmic antineutrophil cytoplasmic antibody‒positive vasculitis]]. The most common cause of death is [[emphysema]]. [[Chronic liver disease]] is the second most common cause of death. Common complications of AATD include [[pneumothorax]], [[pneumonia]], acute exacerbation of airflow obstruction, [[respiratory failure]]. [[Prognosis]] depends on how [[patients]] are identified. [[Patients]] identified as a result of [[screening]] often have excellent [[prognosis]]. Those identified because of their [[symptoms]] have poor [[prognosis]]. | ||
==Natural History== | ==Natural History== | ||
*If left untreated, not all patients with [[Gene|deficient gene]] develop [[Emphysema|symptomatic emphysema]] or [[cirrhosis]]. | *If left untreated, not all patients with [[Gene|deficient gene]] develop [[Emphysema|symptomatic emphysema]] or [[cirrhosis]]. | ||
| Line 25: | Line 25: | ||
* [[Pneumothorax]] | * [[Pneumothorax]] | ||
* [[Pneumonia]] | * [[Pneumonia]] | ||
* | * Acute exacerbation of airflow obstruction | ||
* [[Respiratory failure|Respiratory failure | * [[Respiratory failure|Respiratory failure]] | ||
* [[Bronchiectasis]] | * [[Bronchiectasis]] | ||
* [[Cirrhosis]] or [[liver failure]] | * [[Cirrhosis]] or [[liver failure]] | ||
| Line 33: | Line 33: | ||
==Prognosis== | ==Prognosis== | ||
[[Prognosis]] depends on how [[patients]] are identified. [[Patients]] identified as a result of [[Screening (medicine)|screening]] often have excellent [[prognosis]]. Those identified because of their [[symptoms]] have poor [[prognosis]].<ref name="pmid3264124" /><ref name="pmid9655706" /><ref name="pmid15821195" /> | |||
Those identified because of their [[symptoms]] have poor [[prognosis]]. | |||
Features associated with poor [[prognosis]] include: | Features associated with poor [[prognosis]] include: | ||
*Severe degree of airflow obstruction: | *Severe degree of airflow obstruction: | ||
**[[FEV1]] >50% has a 5-year [[mortality rate]] at 4% | **[[FEV1]] >50% has a 5-year [[mortality rate]] at 4% | ||
**[[FEV1]] within range 35-49% has 5-year [[mortality rate]] at 12% | **[[FEV1]] within range 35-49% has 5-year [[mortality rate]] at 12% | ||
**[[FEV1]] <35 has a 5-year [[mortality rate]] at 50% | **[[FEV1]] <35 has a 5-year [[mortality rate]] at 50% | ||
* A [[Bronchodilators|bronchodilator]] response greater than >12% | * A [[Bronchodilators|bronchodilator]] response greater than >12% | ||
* [[Smoking]] | * [[Smoking]] | ||
* [[Male|Male sex]] | * [[Male|Male sex]] | ||
Latest revision as of 17:48, 22 January 2018
|
Alpha 1-antitrypsin deficiency Microchapters |
|
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Alpha 1-antitrypsin deficiency natural history, complications, and prognosis On the Web |
|
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
|
FDA on Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
|
CDC on Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
|
Alpha 1-antitrypsin deficiency natural history, complications, and prognosis in the news |
|
Blogs on Alpha 1-antitrypsin deficiency natural history, complications, and prognosis |
|
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]
Overview
If left untreated, not all patients with deficient gene develop symptomatic emphysema or cirrhosis. In symptomatic patients, the median time between observation of symptoms and diagnosis is approximately 8 years. The symptoms of alpha1-antitrypsin deficiency (AATD) in the first two decades of life are mainly of associated liver disease progressing to pulmonary manifestations appear later in life. Emphysema is seen in non-smokers in the fifth decade of life and during the fourth decade of life in smokers. Less common associations are panniculitis and cytoplasmic antineutrophil cytoplasmic antibody‒positive vasculitis. The most common cause of death is emphysema. Chronic liver disease is the second most common cause of death. Common complications of AATD include pneumothorax, pneumonia, acute exacerbation of airflow obstruction, respiratory failure. Prognosis depends on how patients are identified. Patients identified as a result of screening often have excellent prognosis. Those identified because of their symptoms have poor prognosis.
Natural History
- If left untreated, not all patients with deficient gene develop symptomatic emphysema or cirrhosis.
- In symptomatic patients, the median time between observation of symptoms and diagnosis is approximately 8 years.[1][2][3]
- The symptoms of alpha1-antitrypsin deficiency (AATD) in the first two decades of life are mainly of associated liver disease progressing to pulmonary manifestations appear later in life.
- Emphysema, is seen in nonsmokers in the fifth decade of life and during the fourth decade of life in smokers.
- Less common associations are panniculitis and cytoplasmic antineutrophil cytoplasmic antibody‒positive vasculitis.
- FEV1 decreases in patients with PiZZ genotype at 51-317 mL per year compared to an estimated decline in healthy individuals at 30 mL/y.
- AATD can be seen in neonates as a cause of neonatal jaundice and hepatitis.
- It may present in infants as cholestatic jaundice and in children as liver cirrhosis or hepatic failure.
- AATD is the leading condition requiring liver transplantation in children.
- PiZZ patients have a 16% likelihood of surviving to age 60 years compared to an 85% likelihood for the general US population.
- The most common cause of death is emphysema. Chronic liver disease is the second most common cause of death.
- Respiratory failure accounts for about 62% of deaths, and complications of chronic liver disease for approximately 13%.
- The mean age of death is 50 years old for nonsmokers and 40 years old for smokers, with only 16% surviving to 60 years old compared to about 85% surviving to 65 years old in the general population.
- Mortality is directly related to FEV1 (forced expiratory volume), and rises exponentially as FEV1 falls below 35% predicted.
Complications
Common complications of AATD include:[3]
- Pneumothorax
- Pneumonia
- Acute exacerbation of airflow obstruction
- Respiratory failure
- Bronchiectasis
- Cirrhosis or liver failure
- Emphysema
- Liver cancer
Prognosis
Prognosis depends on how patients are identified. Patients identified as a result of screening often have excellent prognosis. Those identified because of their symptoms have poor prognosis.[1][2][3]
Features associated with poor prognosis include:
- Severe degree of airflow obstruction:
- FEV1 >50% has a 5-year mortality rate at 4%
- FEV1 within range 35-49% has 5-year mortality rate at 12%
- FEV1 <35 has a 5-year mortality rate at 50%
- A bronchodilator response greater than >12%
- Smoking
- Male sex
References
- ↑ 1.0 1.1 Brantly ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG (1988). "Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms". Am. Rev. Respir. Dis. 138 (2): 327–36. doi:10.1164/ajrccm/138.2.327. PMID 3264124.
- ↑ 2.0 2.1 "Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group". Am. J. Respir. Crit. Care Med. 158 (1): 49–59. 1998. doi:10.1164/ajrccm.158.1.9712017. PMID 9655706.
- ↑ 3.0 3.1 3.2 Stoller JK, Tomashefski J, Crystal RG, Arroliga A, Strange C, Killian DN, Schluchter MD, Wiedemann HP (2005). "Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry". Chest. 127 (4): 1196–204. doi:10.1378/chest.127.4.1196. PMID 15821195.